Literature DB >> 23396947

A novel IRAK1-IKKε signaling axis limits the activation of TAK1-IKKβ downstream of TLR3.

Daniela Bruni1, Jordi Sebastia, Susan Dunne, Martina Schröder, Marion P Butler.   

Abstract

IRAK1 is involved in the regulation of type I IFN production downstream of TLR3. Previous work indicated that IRAK1 negatively regulates TRIF-mediated activation of IRF3 and IRF7. We report that IRAK1 limits the activation of the TLR3-NF-κB pathway. Following TLR3 stimulation, IRAK1-deficient macrophages produced increased levels of IL-6 and IFN-β compared with wild type macrophages. Pharmacological inhibition of TAK1 reduced this increase in IFN-β, together with the heightened activation of IRF3 and p65 found in TLR3-ligand stimulated IRAK1-deficient macrophages. Recently, IKKε and TANK-binding kinase 1 (TBK1) were reported to limit activation of the NF-κB pathway downstream of IL-1R, TNFR1, and TLRs. We show that TBK1 has a positive role in the TLR3-NF-κB pathway, because we detected reduced levels of IL-6 and reduced activation of p65 in TBK1-deficient macrophages. In contrast, we show that IKKε limits the activation of the TLR3-NF-κB pathway. Furthermore, we show that IRAK1 is required for the activation of IKKε downstream of TLR3. We report impaired activation of ERK1/2 in IRAK1- and IKKε-deficient macrophages, a novel finding for both kinases. Importantly, this work provides novel mechanistic insight into the regulation of the TLR3-signaling pathway, providing strong evidence that an IRAK1-IKKε-signaling axis acts to limit the production of both type I IFNs and proinflammatory cytokines by regulating TAK1 activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23396947     DOI: 10.4049/jimmunol.1202042

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  STK4 regulates TLR pathways and protects against chronic inflammation-related hepatocellular carcinoma.

Authors:  Weiyun Li; Jun Xiao; Xin Zhou; Ming Xu; Chaobo Hu; Xiaoyan Xu; Yao Lu; Chang Liu; Shengjie Xue; Lei Nie; Haibin Zhang; Zhiqi Li; Yanbo Zhang; Fu Ji; Lijian Hui; Wufan Tao; Bin Wei; Hongyan Wang
Journal:  J Clin Invest       Date:  2015-10-12       Impact factor: 14.808

2.  Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKε kinase-mediated antiviral response.

Authors:  Ricardo Rajsbaum; Gijs A Versteeg; Sonja Schmid; Ana M Maestre; Alan Belicha-Villanueva; Carles Martínez-Romero; Jenish R Patel; Juliet Morrison; Giuseppe Pisanelli; Lisa Miorin; Maudry Laurent-Rolle; Hong M Moulton; David A Stein; Ana Fernandez-Sesma; Benjamin R tenOever; Adolfo García-Sastre
Journal:  Immunity       Date:  2014-05-29       Impact factor: 31.745

3.  TANK-binding kinase 1 (TBK1) modulates inflammatory hyperalgesia by regulating MAP kinases and NF-κB dependent genes.

Authors:  Christine V Möser; Heike Stephan; Katharina Altenrath; Katharina L Kynast; Otto Q Russe; Katrin Olbrich; Gerd Geisslinger; Ellen Niederberger
Journal:  J Neuroinflammation       Date:  2015-05-23       Impact factor: 8.322

4.  TLR3/TRIF signalling pathway regulates IL-32 and IFN-β secretion through activation of RIP-1 and TRAF in the human cornea.

Authors:  Ga Bin Park; Dae Young Hur; Yeong Seok Kim; Hyun-Kyung Lee; Jae Wook Yang; Daejin Kim
Journal:  J Cell Mol Med       Date:  2015-03-06       Impact factor: 5.310

Review 5.  Innate immune programing by endotoxin and its pathological consequences.

Authors:  Matthew C Morris; Elizabeth A Gilliam; Liwu Li
Journal:  Front Immunol       Date:  2015-01-06       Impact factor: 7.561

6.  TIR-Domain-Containing Adapter-Inducing Interferon-β (TRIF) Is Essential for MPTP-Induced Dopaminergic Neuroprotection via Microglial Cell M1/M2 Modulation.

Authors:  Minghui Shan; Sen Lin; Shurong Li; Yuchen Du; Haixia Zhao; Huarong Hong; Ming Yang; Xi Yang; Yongmei Wu; Liyi Ren; Jiali Peng; Jing Sun; Hongli Zhou; Bingyin Su
Journal:  Front Cell Neurosci       Date:  2017-02-22       Impact factor: 5.505

Review 7.  Phosphatases in toll-like receptors signaling: the unfairly-forgotten.

Authors:  Valérie Lannoy; Anthony Côté-Biron; Claude Asselin; Nathalie Rivard
Journal:  Cell Commun Signal       Date:  2021-01-25       Impact factor: 5.712

8.  Genetically programmed alternative splicing of NEMO mediates an autoinflammatory disease phenotype.

Authors:  Younglang Lee; Alex W Wessel; Jiazhi Xu; Julia G Reinke; Eries Lee; Somin M Kim; Amy P Hsu; Jevgenia Zilberman-Rudenko; Sha Cao; Clinton Enos; Stephen R Brooks; Zuoming Deng; Bin Lin; Adriana A de Jesus; Daniel N Hupalo; Daniela Gp Piotto; Maria T Terreri; Victoria R Dimitriades; Clifton L Dalgard; Steven M Holland; Raphaela Goldbach-Mansky; Richard M Siegel; Eric P Hanson
Journal:  J Clin Invest       Date:  2022-03-15       Impact factor: 14.808

9.  Importance of Validating Antibodies and Small Compound Inhibitors Using Genetic Knockout Studies-T Cell Receptor-Induced CYLD Phosphorylation by IKKε/TBK1 as a Case Study.

Authors:  Marie Lork; Marja Kreike; Jens Staal; Rudi Beyaert
Journal:  Front Cell Dev Biol       Date:  2018-04-10

Review 10.  The Crosstalk Between Hippo-YAP Pathway and Innate Immunity.

Authors:  Shuai Wang; Lili Zhou; Li Ling; Xuli Meng; Feng Chu; Suping Zhang; Fangfang Zhou
Journal:  Front Immunol       Date:  2020-02-27       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.